Hepatitis Drugs Market Size is estimated to grow at a CAGR of 25.0% during the forecast period
The global hepatitis drugs market is
estimated to grow at a CAGR of 25.0% during the forecast period
2022-2030. One of the leading killers in the world is hepatitis, according
to research. Hepatitis type B complications account for over 0.8 million annual
deaths, and hepatitis type C is thought to be the cause of 0.5 million annual
fatalities.
Hepatitis is a serious inflammatory medical disorder that
has a negative impact on the liver. The illness can also have major negative
effects on a person's brain and digestive system. Acute, semi-acute, or chronic infection might
result from it. Viral hepatitis, which can be brought on by any of the five
hepatotropic viruses A, B, C, D, and E, is the most prevalent type of
hepatitis. HAV, HBV, and HCV are the three most well-known kinds of hepatitis
diseases. In addition to bacterial and viral infections, autoimmune illnesses,
excessive alcohol use, toxins, and specific prescription drugs can also
contribute to the condition.
Request
For Free Sample Pages @ https://www.xresearch.biz/request-sample-pages/hepatitis-drugs-market
GROWTH DRIVERS
The increasing prevalence of various types of hepatitis
cases around the world, the rising demand for drugs to treat and manage
hepatitis cases, the rising public awareness of the disease, the aging
population, the rising cost of healthcare, the investments made by public and
private organizations in the development of hepatitis drugs and therapy, and
the rising number of new product launches and regulatory approvals of hepatitis
drugs by authorities are the causes of this.
Additionally, market players are putting an increasingly
greater emphasis on research and development operations in order to secure
approval for various clinical studies for future HCV and HBV medications that
will be sold on the market. Additionally, the launch of brand-new treatments
like second-generation DAAs and interferon-free combination regimens, which are
anticipated to achieve higher SVR and have fewer side effects than current
treatments, is anticipated to create enormous growth opportunities for the
global hepatitis market in the years to come.
Additionally, the growing introduction of generic versions
of existing brands is anticipated to further fuel the growth of the global hepatitis drugs market
during the forecast period. These factors include the rising number of
collaborations and mergers & acquisitions among the major market players
for providing novel solutions to treat hepatitis infections, the emerging trend
of pediatric combination vaccines that aid in the protection against multiple
causative agents.
HEPATITIS DRUGS MARKET SEGMENTATION
By Drug Class
· Interferon
Alphas
· HIV
NRTIs
· Nucleotide
Polymerase / NS5A Inhibitor Combinations
· Hepatitis
C Protease / NS5A Inhibitor Combinations
· NS5A
Inhibitors
· Nucleotide
Polymerase Inhibitors
· Nucleoside
Analogue Antivirals
· Thrombopoiesis
Stimulating Agents
By Disease Type
· Hepatitis
A
· Hepatitis
B
· Hepatitis
C
· Others
By Route of Administration
· Oral
· Injection
By Distribution Channel
· Hospital
Pharmacies
· Retail
Pharmacies
· Online
Pharmacies
By Region
· North
America
· Europe
· Asia
Pacific
· Latin
America
· Middle
East and Africa
KEY COMPANIES IN HEPATITIS DRUGS MARKET
· Novartis
AG
· Dynavax
Technologies Corporation
· F.
Hoffmann-La Roche Ltd.
· Mitsubishi
Tanabe Pharma Corporation
· Bristol-Myers
Squibb Company
· LAURUS
Labs
· Gilead
Sciences Inc.
· Abbvie
Inc.
· Johnson
& Johnson
· Merck
& Co. Inc.
· GlaxoSmithKline
plc
· Vertex
Pharmaceuticals Inc.
· Zydus
Cadila
· Hetero
Healthcare Limited
· Cipla
Inc.
· Other
Players
For
More Information about this Report @ https://www.xresearch.biz/shop/hepatitis-drugs-market
About
Us: -
xResearch is a
market research and consulting organization that uses unique data, expert
analysis, and new technologies to create trusted intelligence on industries.
Our research is focused on delivering an informed and impartial view on
essential market data of industry, and it is primarily driven by an in-depth
study covering the following parameters: Market Sizing and Forecasting, Market
Segmentation, Competitive Analysis, Strategic Assessment and Business
Modelling.
Contact:
Company Name: xResearch
Contact Person: James Lin
Email: sales@xresearch.biz
Phone: +1 718-618-4545
Comments
Post a Comment